Efficacy, safety and pharmacokinetics of 2 concentrations and 2 dosage regimens of CD5789 in subjects with Lamellar Ichthyosis

Trial Profile

Efficacy, safety and pharmacokinetics of 2 concentrations and 2 dosage regimens of CD5789 in subjects with Lamellar Ichthyosis

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Trifarotene (Primary)
  • Indications Ichthyosis; Keratinisation disorders
  • Focus Therapeutic Use
  • Sponsors Galderma
  • Most Recent Events

    • 05 Apr 2014 Status changed from recruiting to completed, as per European Clinical Trials Database record.
    • 22 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top